Statement: More than 5% of the primary trial participants achieved Objective Response (OR).
Primary_evidence: Outcome Measurement:    Objective Response (OR)   Objective response (OR) including complete response (CR) and partial response (PR) according to the Response Evaluation Criteria in Solid Tumours (RECIST) criteria .   Time frame: From first dose of study medication to response measurement, up to 34 month Results 1:    Arm/Group Title: Afatinib 50 mg   Arm/Group Description: Patients received continuous daily dosing with Afatinib 50 mg therapy over 28-day treatment cycles until further disease progression or undue toxicity.   Overall Number of Participants Analyzed: 41   Measure Type: Number   Unit of Measure: Participants  4